IRON Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Disc Medicine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$44.35 |
| 52 Week High | US$77.60 |
| 52 Week Low | US$25.60 |
| Beta | 0 |
| 11 Month Change | 27.96% |
| 3 Month Change | -28.77% |
| 1 Year Change | -4.73% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 122.98% |
Recent News & Updates
Shareholder Returns
| IRON | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.5% | -0.3% | 0.3% |
| 1Y | -4.7% | 11.0% | 22.5% |
Return vs Industry: IRON underperformed the US Biotechs industry which returned 10.7% over the past year.
Return vs Market: IRON underperformed the US Market which returned 22.9% over the past year.
Price Volatility
| IRON volatility | |
|---|---|
| IRON Average Weekly Movement | 15.5% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IRON's share price has been volatile over the past 3 months.
Volatility Over Time: IRON's weekly volatility has increased from 10% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 78 | John Quisel | www.discmedicine.com |
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders.
Disc Medicine, Inc. Fundamentals Summary
| IRON fundamental statistics | |
|---|---|
| Market cap | US$1.29b |
| Earnings (TTM) | -US$80.60m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-16.3x
P/E RatioIs IRON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRON income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$80.60m |
| Earnings | -US$80.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.72 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IRON perform over the long term?
See historical performance and comparison